Bioniz - About Us


Paul Frohna

Paul Frohna, M.D.,Ph.D,Pharm.D.

Chief Medical Officer

Dr. Frohna, is a physician-scientist with over 15 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy and currently serves as our Chief Medical Officer. Prior to this role, Dr. Frohna was the Vice President of Clinical Development and Translational Medicine at Receptos, Inc., where he was responsible for conducting positive Phase 2 clinical trials and two ongoing Phase 3 trials with Ozanimod in relapsing multiple sclerosis (RMS) and ulcerative colitis, and for the clinical development of RPC4046 in eosinophilic esophagitis. Paul’s additional responsibilities included leading drug safety/pharmacovigilance, translational medicine and clinical pharmacology, and participating in partnership discussions that culminated in the acquisition of Receptos by Celgene for $7.2 billion. Prior to Receptos, Paul served as the Chief Medical Officer of ProFibrix, Inc., a Dutch biotech focused on fibrinogen-based therapeutics, for 4 years where he led the successful Raplix™ clinical program until the acquisition by The Medicines Company in 2013. Previously, Paul served as the Vice President of Clinical Development at Fibrogen where he ran programs in CKD anemia and ischemic stroke, and as Medical Director, Specialty Biotherapeutics and Clinical & Experimental Pharmacology at Genentech where he led the Rituxan® MS program and made significant contributions to the Tarceva®, Herceptin® and Raptiva® programs. Dr. Frohna received his MD from Georgetown University with residency training in Internal Medicine, his PhD in Pharmacology from the University of Pennsylvania, and his Pharmacy Degree with Honors from the University of Texas at Austin.